PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT01918202
- Locations
- ๐ธ๐ช
Karolinska Trial Alliance (KTA) M62, Huddinge, Stockholm, Sweden
A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival
- Conditions
- Metastatic Renal Cell Carcinoma
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT01917214
A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT01914796
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT01911273
- Locations
- ๐ฏ๐ต
Kinki University Hospital, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan
๐ฏ๐ตNational Cancer Center Hospital East, Kashiwa, Chiba, Japan
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 921
- Registration Number
- NCT01909453
- Locations
- ๐บ๐ธ
Sanford Cancer Center Oncology Clinic & Pharmacy, Sioux Falls, South Dakota, United States
๐บ๐ธUniversity of Tennessee Medical Center Cancer Institute, Knoxville, Tennessee, United States
๐บ๐ธDr. Dennis B. Kay (Ophthalmologist), Dallas, Texas, United States
A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product
- Conditions
- Healthy
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73
- Registration Number
- NCT01906125
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Overland Park, Kansas, United States
Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT01904747
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New Haven, Connecticut, United States
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
- Conditions
- Chronic Myeloid Leukemia
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 281
- Registration Number
- NCT01903733
- Locations
- ๐ฆ๐ท
Hospital Italiano de la Plata, La Plata, Buenos Aires, Argentina
๐ซ๐ทCHU de CAEN, Caen Cedex 9, France
๐ฎ๐นASST Monza - Ospedale san Gerardo, Monza, Monza AND Brianza, Italy
Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children
- Conditions
- Infections, Meningococcal
- Interventions
- Procedure: Blood Sampling
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 184
- Registration Number
- NCT01900899
- Locations
- ๐ซ๐ฎ
Tampereen yliopisto/ Etela-Helsingin rokotetutkimusklinikka, Helsinki, Finland
๐ซ๐ฎTampereen yliopisto/ Porin rokotetutkimusklinikka, Pori, Finland
๐ซ๐ฎTampereen yliopisto/ Ita-Vantaan rokotetutkimusklinikka, Vantaa, Finland
Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 264
- Registration Number
- NCT01897753
- Locations
- ๐ช๐ธ
Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
๐ช๐ธH.Marquรฉs de Valdecilla, Santander, Cantabria, Spain
๐ช๐ธH. Germans Trias i Pujol, Badalona, Barcelona, Spain